TSXV:APC.H - Post by User
Post by
Goldnboy1on Aug 02, 2022 6:22pm
202 Views
Post# 34866866
$6,000,000,000 Target!!
$6,000,000,000 Target!! Abbvie's Rova-T has had over $6B invested in it.
Rova-T failed in final stage clinical trials due to Off Target Toxicity.
The patents $APC is just being issued will allow them to get Rova-T back to the clinic.
Due to the advanced state of Rova-T. This would mean a fast track to Final stage trials. For this the $APC ADC would be licenced or a joint development agreement signed.
When Trillium signed their joint development agreement with Pfizer to go to clinic. Their stock went from $0.30 to $1.50 in a matter of a few months. Then the Ofizer raise was announced.
At anytime a major like AbbVie or Pfizer could do the same thing here. There will always be a period where the buy up the market before they fund it. I believe this final quarter of 2022 will be the last quarter to buy $apc as a penny stock.
One of $APC's patents have been dubbed by the US patent office as superior to a patent owned by Pfizer. Pfizer acquired this patent in 2009. But they have failed to commercialize it.
$APC's patent runs circles around theirs. If they already care enough about this market to spend tens of millions on an inferior patent a decade ago. Just imagine what they might pay for the answer they are looking for today!
The majors are coming!! Long and strong!!